Press releases

08 Apr 2024

University of Eastern Finland (UEF) and Cumulus Oncology announce new collaboration

Read more

01 Feb 2024

Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation

Read more

08 Jan 2024

Cumulus Oncology raises £9m in seed financing

Read more

17 Jul 2023

Cumulus Oncology and leadXpro Announce Collaboration to Develop Small Molecules against Novel Cancer-Focused GPCR Targets

Read more

07 Feb 2023

Nodus Oncology Secures £2.4m ($2.9m) Investment

Read more

08 Sept 2022

Nodus Oncology announces acquisition of Basilea Pharmaceutica’s PARG inhibitor programme

Read more

06 Sept 2022

Nodus Oncology launches, founded by Cumulus Oncology and in partnership with the Lead Discovery Center, to focus on developing first and best-in-class molecules inhibiting novel DNA damage response targets

Read more

22 Mar 2022

Edinburgh cancer discovery accelerator Cumulus hires Chief Scientific Officer with 'invaluable' skills

Read more

22 Feb 2022

Cumulus Oncology Secures £4.1m ($5.6m) Investment Led by Eos Advisory

Read more

19 Sept 2021

Cumulus Oncology appoints Edinburgh Uni neuroscience graduate as Chief Operating Officer

Read more

22 Mar 2021

LDC and Cumulus Oncology announce collaboration

Read more

13 Jul 2020

Eos Backs Europe's First Oncology Drug Discovery Accelerator Cumulus

Read more

Get in touch

We are interested in talking with asset holders from different sectors, including Universities, Drug Discovery groups as well as Biotech and Pharma companies re-prioritising their oncology portfolio.